-
Recent Posts
Recent Comments
Patrick J. Halloran,… on Shire Development, LLC et al.… Kevin E Noonan on Shire Development, LLC et al.… Qualities of a Good… on Edwards Life Sciences AG et al… Archives
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- Conception and Reduction to Practice
- Contributory Infringement
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Expert Testimony
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Means-plus-function
- Method claims
- Negative Limitations
- Obviousness
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Prosecution History Estoppel
- Public Use
- Reexamination
- Reissue
- Royalties
- Software
- Summary Judgment
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unjust enrichment
- Venue
- Willfullness
- Written description
Meta
- America Invents Act Anticipation (35 USC 102) Appeal Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Collateral estoppel Damages Doctrine of equivalents Expert Testimony Generics / ANDA Indefiniteness Inducement to Infringe Inequitable Conduct Infringement Injunction Inter Parties Review (IPR) Inventorship IPR Means-plus-function Obviousness Patentability Preamble Prosecution History Estoppel Reexamination Trademarks Uncategorized Willfullness Written description
Category Archives: Inter Parties Review (IPR)
Ignite USA, LLC v. CamelBak Products, LLC
Docket No. 2016-2747 (IPR2015-01034) PROST, WALLACH, TARANTO October 12, 2017 Non-precedential Brief summary: Claim construction and obviousness determination in PTAB FWD regarding Ignite’s patent affirmed as supported by substantial evidence. Summary: Ignite appealed PTAB final written decision following IPR finding … Continue reading
Owens Corning v. Fast Felt Corporation
Docket No. 2016-2613 (IPR2015-00650) NEWMAN, DYK, TARANTO October 11, 2017 Brief summary: Board decision that Owens did not show obviousness during IPR reversed (not remanded) under a corrected claim construction. Summary: Fast Felt sued Owens for infringement of its US … Continue reading
Organik Kimya AS v. Rohm and Hass Company
Docket No. 2015-1983, -2001 PROST, NEWMAN, TARANTO October 11, 2017 Brief summary: PTAB decision following IPR sustaining the patentability of Rohm’s patents relating to polymers for use in paints and the like affirmed (e.g., Organik did not present any “evidence … Continue reading
Aqua Products, Inc. v. Joseph Matal (USPTO)
Docket No. 2015-1177 (IPR2013-00159) En banc Opinion October 4, 2017 Brief summary: Earlier appeal of IPR decision remanded “to the Board to issue a final decision under § 318(a) assessing the patentability of the proposed substituted claims without placing the … Continue reading
Posted in Inter Parties Review (IPR), IPR
Leave a comment
NFC Technology, LLC v. Joseph Matal (USPTO)
Docket No. 2016-1808 (IPR2014-01198) LOURIE, REYNA, STOLL September 20, 2017 Brief summary: PTAB IPR FWD of invalidity for obviousness reversed and remanded as sufficient evidence corroborated inventor’s testimony regarding conception, and it must decide whether a prototype embodied the claimed … Continue reading
Mylan Laboratories Limited v. Aventis Pharma S.A.
Case No. IPR2016-00712 (U.S. Pat. No. 8,927,592 B2) Final Written Decision September 21, 2017 Brief summary: FWD concludes Mylan showed the ‘592 claims are invalid for obviousness. Summary: The ‘592 patent is one of three patents listed on the FDA … Continue reading
Posted in Inter Parties Review (IPR), IPR, Obviousness
Leave a comment
Enova Technology Corp. v. Seagate Technology (US) Holdings Inc., et al.
2016-1749, -1751, -2039 (IPR Nos. 2014-01178, -01297, -01449) LOURIE, WALLACH, STOLL September 6, 2017 Non-precedential Brief summary: Board FWD of obviousness affirmed for various reasons. Summary: Enova appealed final written decisions (FWDs) after IPR that claims 1-53 of its US … Continue reading
Posted in Inter Parties Review (IPR), IPR, Obviousness
Leave a comment
